Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Same Day Discharge vs Overnight Hospitalization with Abciximab After Trans-Radial Coronary Stenting
NCT00169819Phase 4Completed
- Sponsor
- Université Laval
- Start
- Oct 2003
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of abciximab in coronary artery disease (CAD) (2 arms), sponsored by Université Laval. Primary endpoint: Composite of death, myocardial infarction, repeat hospitalization, urgent revascularization, severe thrombocytopenia, access site complications and major bleedings at 30 days. Started Oct 2003; status: completed.
02
Drugs
abciximab
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT00169819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00169819.